APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-amyloid-β Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti-amyloid-β Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025173 pages

Choose your research edition.

Industry ResearchAnti-amyloid-β Monoclonal Antibodies Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-amyloid-β Monoclonal Antibodies Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Anti-amyloid-β Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-amyloid-β Monoclonal Antibodies Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-amyloid-β Monoclonal Antibodies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-amyloid-β Monoclonal Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti-amyloid-β Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-amyloid-β Monoclonal Antibodies include Eisai, Eli Lilly and Biogen, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-amyloid-β Monoclonal Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-amyloid-β Monoclonal Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-amyloid-β Monoclonal Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-amyloid-β Monoclonal Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-amyloid-β Monoclonal Antibodies Segment by Company

Eisai

Eli Lilly

Biogen

Anti-amyloid-β Monoclonal Antibodies Segment by Type

Lecanemab

Donanemab

Anti-amyloid-β Monoclonal Antibodies Segment by Application

Hospital

Clinic

Other

Anti-amyloid-β Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-amyloid-β Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-amyloid-β Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-amyloid-β Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-amyloid-β Monoclonal Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-amyloid-β Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti-amyloid-β Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti-amyloid-β Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti-amyloid-β Monoclonal Antibodies Industry Trends Table 2. Anti-amyloid-β Monoclonal Antibodies Industry Drivers Table 3. Anti-amyloid-β Monoclonal Antibodies Industry Opportunities and Challenges Table 4. Anti-amyloid-β Monoclonal Antibodies Industry Restraints Table 5. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti-amyloid-β Monoclonal Antibodies Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Manufacturers Table 9. Global Anti-amyloid-β Monoclonal Antibodies Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Anti-amyloid-β Monoclonal Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti-amyloid-β Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti-amyloid-β Monoclonal Antibodies Manufacturers, Product Type & Application Table 13. Global Anti-amyloid-β Monoclonal Antibodies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-amyloid-β Monoclonal Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lecanemab Table 17. Major Manufacturers of Donanemab Table 18. Global Anti-amyloid-β Monoclonal Antibodies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Anti-amyloid-β Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 20. Global Anti-amyloid-β Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 21. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Type (2021-2026) Table 22. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Type (2027-2032) Table 23. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type (2021-2026) & (K Units) Table 25. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type (2027-2032) & (K Units) Table 26. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Type (2021-2026) Table 27. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Major Manufacturers of Other Table 31. Global Anti-amyloid-β Monoclonal Antibodies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Anti-amyloid-β Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 33. Global Anti-amyloid-β Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 34. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Application (2021-2026) Table 35. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Application (2027-2032) Table 36. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application (2021-2026) & (K Units) Table 38. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application (2027-2032) & (K Units) Table 39. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Application (2021-2026) Table 40. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Application (2027-2032) Table 41. Global Anti-amyloid-β Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 43. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 44. Global Anti-amyloid-β Monoclonal Antibodies Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Anti-amyloid-β Monoclonal Antibodies Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 48. North America Anti-amyloid-β Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 49. Europe Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 51. Europe Anti-amyloid-β Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 58. Global Anti-amyloid-β Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Region (2021-2026) Table 62. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Region (2027-2032) Table 63. Eisai Company Information Table 64. Eisai Business Overview Table 65. Eisai Anti-amyloid-β Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Eisai Anti-amyloid-β Monoclonal Antibodies Product Portfolio Table 67. Eisai Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Anti-amyloid-β Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly Anti-amyloid-β Monoclonal Antibodies Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Biogen Company Information Table 74. Biogen Business Overview Table 75. Biogen Anti-amyloid-β Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Biogen Anti-amyloid-β Monoclonal Antibodies Product Portfolio Table 77. Biogen Recent Development Table 78. Key Raw Materials Table 79. Raw Materials Key Suppliers Table 80. Anti-amyloid-β Monoclonal Antibodies Distributors List Table 81. Anti-amyloid-β Monoclonal Antibodies Customers List Table 82. Research Programs/Design for This Report Table 83. Authors List of This Report Table 84. Secondary Sources Table 85. Primary Sources List of Figures Figure 1. Anti-amyloid-β Monoclonal Antibodies Product Image Figure 2. Global Anti-amyloid-β Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-amyloid-β Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-amyloid-β Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 5. Global Anti-amyloid-β Monoclonal Antibodies Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anti-amyloid-β Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lecanemab Image Figure 9. Donanemab Image Figure 10. Global Anti-amyloid-β Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Type (2021-2032) Figure 13. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Other Image Figure 19. Global Anti-amyloid-β Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Application (2021-2032) Figure 22. Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Application (2021-2032) Figure 25. North America Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 27. U.S. Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 32. Germany Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 39. China Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 47. Brazil Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Anti-amyloid-β Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Anti-amyloid-β Monoclonal Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 58. North America Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 60. Europe Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Anti-amyloid-β Monoclonal Antibodies Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Anti-amyloid-β Monoclonal Antibodies Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Lecanemab
  • Donanemab
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Eisai
  • Eli Lilly
  • Biogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-amyloid-β Monoclonal Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-amyloid-β Monoclonal Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti-amyloid-β Monoclonal Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti-amyloid-β Monoclonal Antibodies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti-amyloid-β Monoclonal Antibodies Market Dynamics
  1. 2.1 Anti-amyloid-β Monoclonal Antibodies Industry Trends
  2. 2.2 Anti-amyloid-β Monoclonal Antibodies Industry Drivers
  3. 2.3 Anti-amyloid-β Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Anti-amyloid-β Monoclonal Antibodies Industry Restraints
3 Anti-amyloid-β Monoclonal Antibodies Market by Manufacturers
  1. 3.1 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti-amyloid-β Monoclonal Antibodies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti-amyloid-β Monoclonal Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-amyloid-β Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti-amyloid-β Monoclonal Antibodies Manufacturers, Product Type & Application
  7. 3.7 Global Anti-amyloid-β Monoclonal Antibodies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-amyloid-β Monoclonal Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-amyloid-β Monoclonal Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-amyloid-β Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
4 Anti-amyloid-β Monoclonal Antibodies Market by Type
  1. 4.1 Anti-amyloid-β Monoclonal Antibodies Type Introduction
  2. 4.1.1 Lecanemab
  3. 4.1.2 Donanemab
  4. 4.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Type
  5. 4.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Type (2021-2032)
  7. 4.2.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Type (2021-2032)
  8. 4.3 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type
  9. 4.3.1 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Type (2021-2032)
  11. 4.3.3 Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
5 Anti-amyloid-β Monoclonal Antibodies Market by Application
  1. 5.1 Anti-amyloid-β Monoclonal Antibodies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Application
  6. 5.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Application (2021-2032)
  8. 5.2.3 Global Anti-amyloid-β Monoclonal Antibodies Sales Market Share by Application (2021-2032)
  9. 5.3 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application
  10. 5.3.1 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Application (2021-2032)
  12. 5.3.3 Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
6 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region
  1. 6.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-amyloid-β Monoclonal Antibodies Sales by Region (2021-2026)
  4. 6.2.2 Global Anti-amyloid-β Monoclonal Antibodies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region
  1. 7.1 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region
  2. 7.1.1 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti-amyloid-β Monoclonal Antibodies Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti-amyloid-β Monoclonal Antibodies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032)
  8. 7.2.2 North America Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032)
  11. 7.3.2 Europe Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti-amyloid-β Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Anti-amyloid-β Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Anti-amyloid-β Monoclonal Antibodies Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Anti-amyloid-β Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Anti-amyloid-β Monoclonal Antibodies Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Biogen
  14. 8.3.1 Biogen Company Information
  15. 8.3.2 Biogen Business Overview
  16. 8.3.3 Biogen Anti-amyloid-β Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Biogen Anti-amyloid-β Monoclonal Antibodies Product Portfolio
  18. 8.3.5 Biogen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-amyloid-β Monoclonal Antibodies Value Chain Analysis
  2. 9.1.1 Anti-amyloid-β Monoclonal Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-amyloid-β Monoclonal Antibodies Production Mode & Process
  6. 9.2 Anti-amyloid-β Monoclonal Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-amyloid-β Monoclonal Antibodies Distributors
  9. 9.2.3 Anti-amyloid-β Monoclonal Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst